FDA Committed To Advancing Its Regulatory Science Capacity
This article was originally published in The Rose Sheet
Executive Summary
FDA cites "advances in the application of nanotechnology" among scientific "breakthroughs" that are revolutionizing the health-care community's ability to treat disease, making the notion of personalized care a reality and demanding more FDA involvement
You may also be interested in...
FDA Budget Issues Creep Into Strategic Priorities
“Given the limited availability of investment capital for medical product development, early clarification of regulatory requirements is critical,” FDA says. Agency officials included stewardship, such as doing more with less funding, among the cross-cutting strategic priorities in its draft strategic priorities document for 2014-2018.
FDA Prioritizes New Technologies, Nano Included, In Regulatory Science Plan
FDA plans to invest in eight priority areas for regulatory science, with the goal of improving its handle on emerging technologies such as nanotechnology, elevating the quality of clinical trial data and developing better tools for reviewing manufacturing systems, according to a strategic plan.
FDA Prioritizes New Technologies, Nano Included, In Regulatory Science Plan
FDA plans to invest in eight priority areas for regulatory science, with the goal of improving its handle on emerging technologies such as nanotechnology, elevating the quality of clinical trial data and developing better tools for reviewing manufacturing systems, according to a strategic plan.